Lyell Immunopharma Ownership | Who Owns Lyell Immunopharma?
Lyell Immunopharma Ownership Summary
Lyell Immunopharma is owned by 4.73% institutional investors, 27.70% insiders, and 67.57% retail investors. Arch venture management is the largest institutional shareholder, holding 18.65% of LYEL shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.44% of its assets in Lyell Immunopharma shares.
LYEL Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Lyell Immunopharma | 4.73% | 27.70% | 67.57% |
| Sector | Healthcare Stocks | 232.51% | 10.72% | -143.22% |
| Industry | Biotech Stocks | 384.55% | 10.58% | -295.13% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Arch venture management | 2.76M | 18.65% | $44.81M |
| Gsk | 1.51M | 8.28% | $46.56M |
| Foresite capital management iv | 800.40K | 5.41% | $13.00M |
| Blackrock | 13.50M | 5.31% | $19.57M |
| Vanguard group | 826.43K | 4.52% | $25.44M |
| Almitas capital | 577.81K | 3.91% | $9.38M |
| Foresite capital management v | 477.08K | 3.23% | $7.75M |
| Venbio partners | 473.48K | 3.20% | $7.69M |
| Wuxi apptec | 7.68M | 3.02% | $11.14M |
| Alphabet | 293.26K | 1.98% | $4.76M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Wuxi apptec | 7.68M | 47.74% | $11.14M |
| Arch venture management | 2.76M | 9.10% | $44.81M |
| Foresite capital management v | 477.08K | 7.12% | $7.75M |
| Foresite capital management iv | 800.40K | 7.12% | $13.00M |
| Gsk | 1.51M | 5.83% | $46.56M |
| Venbio partners | 473.48K | 4.36% | $7.69M |
| Almitas capital | 577.81K | 2.15% | $9.38M |
| Takeda pharmaceutical | 41.16K | 1.86% | $363.91K |
| Decheng capital | 595.47K | 1.33% | $5.26M |
| Mic capital management uk llp | 87.03K | 0.28% | $1.41M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Gsk | 1.51M | 5.83% | 1.51M |
| Arch venture management | 2.76M | 9.10% | 938.44K |
| D. e. shaw | 966.26K | 0.00% | 493.64K |
| Wellington management group llp | 367.68K | 0.00% | 367.68K |
| Millennium management | 957.51K | 0.00% | 247.44K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Decheng capital | 595.47K | 1.33% | -11.31M |
| Opaleye management | - | - | -1.40M |
| Balyasny asset management | - | - | -1.20M |
| Mwg management | - | - | -1.01M |
| Invenomic capital management lp | - | - | -871.52K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Gsk | 1.51M | 5.83% | 1.51M | $46.56M |
| Wellington management group llp | 367.68K | 0.00% | 367.68K | $533.13K |
| Goldman sachs group | 96.67K | 0.00% | 96.67K | $2.98M |
| Jane street group | 12.41K | 0.00% | 12.41K | $381.95K |
| Trexquant investment lp | 10.28K | 0.00% | 10.28K | $166.87K |
Sold Out
| Holder | Change |
|---|---|
| Eversource wealth advisors | -1.00 |
| Ifp advisors | -1.00 |
| Pnc financial services group | -4.00 |
| True wealth design | -23.00 |
| Nelson, van denburg & campbell wealth management group | -34.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 10 | -82.76% | 864,633 | -91.03% | 4 | 0.11% | 4 | -80.00% | 2 | -89.47% |
| Sep 30, 2025 | 15 | -78.26% | 1,180,540 | -87.25% | 7 | 0.20% | 6 | -50.00% | 4 | -92.86% |
| Jun 30, 2025 | 68 | -39.82% | 9,256,423 | -93.92% | 62 | 939.01% | 12 | -68.42% | 55 | 52.78% |
| Mar 31, 2025 | 112 | 8.74% | 152,309,719 | 1.35% | 51 | 1.50% | 38 | -26.92% | 37 | 48.00% |
| Dec 31, 2024 | 97 | -17.09% | 146,305,210 | 13.92% | 57 | 2.27% | 47 | -6.00% | 24 | -22.58% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 276.12K | 1.44% | -6.10K |
| iShares Russell 2000 ETF | 4.13M | 1.39% | - |
| T. Rowe Price Health Sciences | 212.18K | 1.10% | -2.38K |
| Biotech Growth Ord | 2.88M | 0.99% | - |
| Vanguard Small Cap Index | 2.24M | 0.87% | 5.37K |
| iShares Russell 2000 Value ETF | 1.47M | 0.49% | - |
| Vanguard Small Cap Growth Index Inv | 1.25M | 0.49% | -5.54K |
| Vanguard Institutional Extnd Mkt Idx Tr | 91.69K | 0.48% | -37.12K |
| Fidelity Small Cap Index | 1.63M | 0.44% | - |
| State St Russell Sm/Mid Cp® Indx NL Cl C | 1.18M | 0.40% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Feb 11, 2026 | Seely Lynn | President and CEO | Sell | $174.37K |
| Feb 11, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | $28.91K |
| Feb 11, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | $39.08K |
| Feb 10, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | $2.52K |
| Feb 10, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | $3.40K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 7 |
| 2025 Q4 | - | 6 |
| 2025 Q3 | - | 12 |
| 2025 Q2 | - | - |
| 2025 Q1 | 5 | - |
LYEL Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools